Literature DB >> 30228707

Radiation Therapy for Prostate Cancer.

Hiram A Gay1, Jeff M Michalski1.   

Abstract

Annually, there are nearly 3000 new cases and 500 deaths from prostate cancer in Missouri. When treatment is appropriate and necessary, radiotherapy offers similar cure rates to prostatectomy, with fewer long-term sexual side effects and little effect on urinary continence. Radiotherapy is delivered with external beam or implanted radioactive sources (brachytherapy). In high-risk disease, combinations of external beam and brachytherapy offers improved biochemical control. Following prostatectomy, salvage radiotherapy should be initiated as soon as possible.

Entities:  

Mesh:

Year:  2018        PMID: 30228707      PMCID: PMC6139853     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  8 in total

1.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

2.  Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.

Authors:  Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Daniel A Hamstra; Walter Bosch; Hiram Gay; Jeff Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-23       Impact factor: 7.038

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

4.  Stereotactic body radiation therapy for prostate cancer: Rational and reasonable.

Authors:  Patrick Kupelian; Niraj H Mehta; Chris King; Michael Steinberg; Steven E Finkelstein; Eduardo Fernandez
Journal:  Pract Radiat Oncol       Date:  2014-10-18

5.  ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Authors:  Sree Rodda; Scott Tyldesley; W James Morris; Mira Keyes; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-01-06       Impact factor: 7.038

6.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Authors:  J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

7.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

8.  Prostate cancer. NCCN clinical practice guidelines in oncology.

Authors: 
Journal:  J Natl Compr Canc Netw       Date:  2004-05       Impact factor: 11.908

  8 in total
  6 in total

Review 1.  Advances in Assistive Electronic Device Solutions for Urology.

Authors:  Kieran Holmes-Martin; Minghui Zhu; Shujun Xiao; Faezeh Arab Hassani
Journal:  Micromachines (Basel)       Date:  2022-03-30       Impact factor: 3.523

2.  Silibinin Radiosensitizes EGF Receptor-knockdown Prostate Cancer Cells by Attenuating DNA Repair Pathways.

Authors:  Mohit Rajput; Deepali Mishra; Kunal Kumar; Rana P Singh
Journal:  J Cancer Prev       Date:  2022-09-30

3.  Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer.

Authors:  Manish Thiruvalluvan; Sandrine Billet; Neil A Bhowmick
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

Review 4.  MicroRNA mediated therapeutic effects of natural agents in prostate cancer.

Authors:  Km Anjaly; A B Tiku
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

5.  Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Authors:  Raja Khauli; Robson Ferrigno; Gustavo Guimarães; Muhammad Bulbulan; Pedro Luiz Serrano Uson Junior; Bernardo Salvajoli; Daniel Moore Freitas Palhares; Douglas Racy; Erlon Gil; Fernando Freire de Arruda; Gustavo Caserta Lemos; Gustavo Franco Carvalhal; Icaro Thiago de Carvalho; Igor Austin Fernandes Martins; Ivan Frederico Pinto Gimpel; João Victor Salvajoli; José Luis Chambo; José Pontes; Leopoldo Alves Ribeiro Filho; Lucas Nogueira; Marcelo Roberto Pereira Freitas; Marcelo Wroclawski; Marco Antonio Arap; Marcus Vinicius Sadi; Rafael Coelho; Rafael Gadia; Rodrigo Antonio Ledezma Roja; Rodrigo de Moraes Hanriot; Ronaldo Baroni; Stenio Zequi; William Carlos Nahas; Wladimir Alfer; Fernando Cotait Maluf
Journal:  JCO Glob Oncol       Date:  2021-04

6.  Cost Analysis of Selected Radiotherapeutic Modalities for Prostate Cancer Treatment-Czech Republic Case Study for the Purposes of Hospital Based HTA.

Authors:  Petra Hospodková; Tomáš Husár; Barbora Klíčová; Lucie Severová; Karel Šrédl; Roman Svoboda
Journal:  Healthcare (Basel)       Date:  2021-01-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.